×
About 1,218 results

ALLMedicine™ Acute Pyelonephritis Center

Research & Reviews  348 results

Immunomodulation therapy offers new molecular strategies to treat UTI.
https://doi.org/10.1038/s41585-022-00602-4 10.1016/j.molimm.2003.10.005 10.1038/nri2194 10.3109/08830185.2010.529976 10.1038/s41585-021-00477-x 10.1038/nrurol.2010.101 10.1038/s41579-020-0324-0 10.1038/s41585-020-0350-8 10.1016/j.it.2021.01.003 10.1111/imr.12621 10.1371/journal.ppat.1001109 10.1126/scitranslmed.aaf1156 10.1371/journal.ppat.1005848 10.1038/s41598-018-28634-0 10.1084/jem.192.6.881 10.1086/318848 10.1002/eji.200535149 10.4049/jimmunol.0902386 10.1016/j.immuni.2014.02.015 10.1016/j.kint.2017.12.006 10.1152/ajprenal.00471.2016 10.1038/mi.2015.7 10.1073/pnas.1500374112 10.1038/mi.2015.44 10.1038/mi.2013.72 10.1093/infdis/143.3.404 10.1111/j.1365-3083.1985.tb01435.x 10.1016/S0022-5347(01)62142-6 10.1038/nrurol.2011.100 10.1172/JCI82424 10.1172/jci.insight.122998 10.1128/iai.46.3.839-844.1984 10.1016/S0022-5347(17)36260-2 10.1016/j.chom.2013.11.004 10.1371/journal.ppat.1005044 10.1038/nrurol.2010.190 10.1093/infdis/171.3.625 10.1038/nrmicro818 10.1086/514920 10.1016/S1369-5274(00)00242-3 10.1128/AAC.37.11.2255 10.1128/AAC.00862-20 10.1056/NEJMra1007755 10.1016/j.diagmicrobio.2013.11.011 10.3109/07853890109002101 10.1016/S0140-6736(76)90788-1 10.1056/NEJMp058032 10.1097/MOU.0000000000000364 10.3389/fped.2018.00277 10.1128/iai.57.11.3383-3388.1989 10.1016/S0966-842X(00)88941-6 10.1016/j.mpmed.2007.05.009 10.1056/NEJM196408272710905 10.1056/NEJM198605013141804 10.1097/01.CCM.0000194535.82812.BA 10.1136/bmj.l525 10.1001/archpedi.154.4.339 10.1007/s00467-003-1109-1 10.1111/j.1651-2227.2012.02785.x 10.1097/HJH.0000000000000234 10.1111/j.1574-6968.1980.tb05064.x 10.1093/infdis/158.1.29 10.1128/iai.59.12.4357-4362.1991 10.1128/CMR.4.1.80 10.1128/iai.37.1.286-291.1982 10.1093/clinids/17.3.448 10.1016/S0163-4453(88)93947-3 10.1038/35015091 10.1128/IAI.00075-08 10.1016/j.toxicon.2017.10.016 10.1016/0924-8579(94)90039-6 10.1111/j.1749-6632.1994.tb44247.x 10.4049/jimmunol.166.2.1148 10.1086/512620 10.1038/ki.2008.105 10.1007/s12223-014-0303-9 10.1126/science.282.5396.2085 10.1016/S0952-7915(99)00046-1 10.4049/jimmunol.178.8.4717 10.1016/j.mib.2007.12.001 10.1084/jem.183.3.1037 10.1046/j.1365-2958.1998.01017.x 10.1128/iai.58.9.3073-3077.1990 10.1073/pnas.93.18.9630 10.1073/pnas.96.14.8110 10.1074/jbc.M008610200 10.1074/jbc.M600877200 10.1371/journal.ppat.0030100 10.1038/nature01182 10.1371/journal.ppat.1001120 10.1128/iai.65.8.3451-3456.1997 10.1086/318848 10.1073/pnas.93.18.9827 10.1128/microbiolspec.UTI-0015-2012 10.1371/journal.ppat.1007671 10.1128/iai.61.2.602-609.1993 10.1111/j.1462-5822.2008.01230.x 10.1016/j.cell.2014.01.006 10.1371/journal.ppat.1004818 10.1128/IAI.00327-18 10.4049/jimmunol.165.9.5287 10.1371/journal.ppat.1002619 10.1038/35074106 10.1111/j.1744-313X.2007.00709.x 10.1016/j.chom.2007.05.007 10.1371/journal.pone.0005990 10.1371/journal.pone.0008300 10.1086/322030 10.1086/317599 10.1111/j.1523-1755.2005.00060.x 10.1172/JCI116650 10.1038/381077a0 10.1016/j.ebiom.2014.10.011 10.1038/s41423-020-0412-0 10.1172/jci.insight.97626 10.3389/fcimb.2017.00113 10.1152/ajprenal.00344.2014 10.1111/j.1744-313X.2012.01096.x 10.1016/j.juro.2006.10.037 10.1097/INF.0b013e3181ff84ff 10.1016/j.jpurol.2017.05.025 10.1016/j.jpeds.2010.08.006 10.1186/1471-2334-12-273 10.1016/j.juro.2014.03.092 10.1093/infdis/166.3.653 10.1007/s00467-007-0670-4 10.1056/NEJMoa1208760 10.1056/NEJMoa1209026 10.1021/ja505986a 10.1001/jama.2015.1241 10.1042/CS20050162 10.4155/tde.12.136 10.1196/annals.1281.008 10.1038/sj.cgt.7700931 10.1186/1741-7015-8-30 10.1136/bmj.h6544 10.1128/iai.58.7.2056-2060.1990 10.1172/JCI1861 10.1038/nm1407 10.1111/j.1348-0421.2011.00315.x 10.1128/IAI.70.6.3053-3060.2002 10.1007/s00109-007-0256-4 10.1038/ki.2011.109 10.1128/IAI.01393-13 10.1172/JCI71630 10.1016/S1097-2765(02)00708-6 10.1093/infdis/jiu577 10.1056/NEJMcp030027 10.1056/NEJMcp1104429 10.1056/NEJM199310283291808 10.1016/j.urology.2007.12.091 10.1016/j.urology.2008.09.014 10.1128/iai.40.1.265-272.1983 10.1128/iai.50.2.370-377.1985 10.1128/iai.55.2.373-380.1987 10.1128/iai.55.5.1224-1232.1987 10.1128/jcm.25.12.2253-2257.1987 10.1146/annurev.immunol.021908.132612 10.1016/j.immuni.2011.12.002 10.1371/journal.pone.0037689 10.1038/nri1391 10.1136/ard.2005.048371 10.1186/ar4303 10.1586/1744666X.2014.861325 10.1016/S2665-9913(20)30164-8 10.1038/ncomms10791 10.1016/S2665-9913(21)00216-2 10.1111/j.1432-2277.2008.00651.x 10.1172/JCI60777 10.1038/s41577-019-0147-2 10.1007/s002960050065 10.1371/journal.pone.0017360 10.1007/s00726-014-1736-9 10.1152/ajprenal.00187.2002 10.1016/S0002-9440(10)64944-9 10.1086/651275 10.1016/j.euros.2021.07.003 10.1016/S0090-4295(99)80327-6 10.1016/j.juro.2006.09.032 10.1016/j.eururo.2007.09.019 10.1186/1471-2490-9-16 10.1007/s10753-018-0888-2 10.1016/j.juro.2012.08.189 10.1517/13543780903379530 10.1128/iai.40.2.529-533.1983 10.1097/00005392-199909010-00067 10.1136/bmj.j4784 10.1371/journal.pmed.1002569 10.1038/nm1572 10.1172/JCI66451 10.1172/JCI140333 10.1038/nsmb763 10.1172/JCI152693 10.1172/JCI152693 10.1128/IAI.74.1.594-601.2006 10.1038/nm1734 10.1073/pnas.1215770110 10.1128/JCM.01227-09 10.1084/jem.20041442 10.1038/nrc904 10.1182/blood-2017-11-742577 10.1111/all.14149 10.1126/science.2911736 10.1002/dvdy.21841 10.1083/jcb.112.1.13 10.1038/s41587-020-00805-3 10.1093/infdis/139.3.329 10.1007/BF00256954 10.1038/298560a0 10.1038/328084a0 10.1038/nature22972 10.1038/265623a0 10.1073/pnas.0902179106 10.1126/scitranslmed.3003021 10.1038/s41579-020-00506-3 10.1128/iai.59.3.1153-1161.1991 10.1086/315258 10.1073/pnas.1606324113 10.1038/ki.1975.118 10.1128/iai.17.2.286-289.1977 10.1097/01.ju.0000116123.05160.43 10.1128/IAI.71.12.7164-7169.2003 10.1371/journal.ppat.1000586 10.1016/j.micpath.2017.07.037 10.1016/j.eursup.2009.07.002 10.1016/S0022-5347(01)64671-8 10.1016/S1473-3099(17)30108-1 10.1038/mi.2016.112 10.1111/bju.14606 10.1111/j.1464-410X.1990.tb14649.x 10.1128/mBio.00555-20 10.1016/j.biocel.2007.07.003 10.1128/IAI.00076-06 10.1016/j.mimet.2009.04.013 10.1128/IAI.00337-07 10.1128/JB.01744-06 10.1128/IAI.00752-12 10.1128/mr.47.4.510-550.1983 10.1016/S0022-3476(86)80110-X 10.1086/318857 10.1080/21645515.2020.1834807 10.1038/s41590-020-0688-3 10.1073/pnas.2026461118
Nature Reviews. Urology; Butler D, Ambite I et. al.

Jun 23rd, 2022 - Innovative solutions are needed for the treatment of bacterial infections, and a range of antibacterial molecules have been explored as alternatives to antibiotics. A different approach is to investigate the immune system of the host for new ways ...

The Validity of the Quick Renal MRI in Pediatric Kidney Disease
https://clinicaltrials.gov/ct2/show/NCT03959163

Jun 23rd, 2022 - Children born with congenital anomalies of the urinary tract are susceptible to kidney infections and scarring. They form a high risk group for developing renal insufficiency in adulthood. A basic tenet in pediatric urology is that kidney infectio...

Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents
https://clinicaltrials.gov/ct2/show/NCT04700787

Jun 13th, 2022 - After being informed about the study and potential risks, all patients giving written informed consent will be screened for eligibility. Hospitalized patients who are 12-18 years of age and who are receiving background antibiotic treatment for unc...

see more →

Guidelines  1 results

ACR Appropriateness Criteria® Acute Pyelonephritis.
https://doi.org/10.1016/j.jacr.2018.09.011
Journal of the American College of Radiology : JACR; , Nikolaidis P et. al.

Nov 6th, 2018 - Pyelonephritis refers to infection involving the renal parenchyma and renal pelvis. In most patients, uncomplicated pyelonephritis is diagnosed clinically and responds quickly to appropriate antibiotic treatment. If treatment is delayed, the patie...

see more →

Drugs  66 results see all →

Clinicaltrials.gov  48 results

The Validity of the Quick Renal MRI in Pediatric Kidney Disease
https://clinicaltrials.gov/ct2/show/NCT03959163

Jun 23rd, 2022 - Children born with congenital anomalies of the urinary tract are susceptible to kidney infections and scarring. They form a high risk group for developing renal insufficiency in adulthood. A basic tenet in pediatric urology is that kidney infectio...

Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents
https://clinicaltrials.gov/ct2/show/NCT04700787

Jun 13th, 2022 - After being informed about the study and potential risks, all patients giving written informed consent will be screened for eligibility. Hospitalized patients who are 12-18 years of age and who are receiving background antibiotic treatment for unc...

Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
https://clinicaltrials.gov/ct2/show/NCT04979806

May 10th, 2022 - This is a Phase 3, randomized, double-blind, multicenter, non-inferiority study to evaluate the efficacy, safety, and tolerability of FEP-ZID vs. meropenem in the treatment of hospitalized adults with cUTI or AP. Approximately 504 hospitalized adu...

Diagnostic Imaging of Acute Pyelonephritis
https://clinicaltrials.gov/ct2/show/NCT04651244

Apr 28th, 2022 - Acute pyelonephritis (APN) is an acute infection in the upper urinary tract, which quite frequently is seen in emergency departments (ED). Most often, an infection of the bladder ascends to the kidneys causing APN. In rarer cases, APN occurs becau...

Diagnostic Accuracy of Urine Flow Cytometry in Excluding Bacteruria
https://clinicaltrials.gov/ct2/show/NCT04686292

Apr 20th, 2022 - A prerequisite for the appropriate use of antibiotics is timely access to accurate diagnostic tests, since treatment of acute infections should be initiated within a few hours to avoid serious complications such as bacteremia, sepsis, organ failur...

see more →

News  24 results

Tebipenem Pivoxil Hydrobromide Offers Oral Option for Complex UTIs
https://www.medscape.com/viewarticle/971795

Apr 7th, 2022 - Oral tebipenem pivoxil hydrobromide (TBP-PI-HBr) offers a safe and effective strategy for treating patients with complicated urinary tract infections, according to a new study. Dr Angela Talley "No new oral antibiotic alternative has emerged to tr...

Tebipenem pivoxil hydrobromide offers oral option for complex UTIs
https://www.mdedge.com/internalmedicine/article/253512/infectious-diseases/tebipenem-pivoxil-hydrobromide-offers-oral
Heidi Splete

Apr 6th, 2022 - Oral tebipenem pivoxil hydrobromide (TBP-PI-HBr) offers a safe and effective strategy for treating patients with complicated urinary tract infections, according to a new study. “No new oral antibiotic alternative has emerged to treat these conditi.

UTIs in pregnancy: Managing urethritis, asymptomatic bacteriuria, cystitis, and pyelonephritis
https://www.mdedge.com/obgyn/article/250720/utis-pregnancy-managing-urethritis-asymptomatic-bacteriuria-cystitis-and
Patrick Duff, MD

Jan 13th, 2022 - CASE Pregnant woman with dysuria and suprapubic pain A 25-year-old primigravid woman at 18 weeks of gestation requests evaluation because of the acute onset of frequent urination, dysuria, urination hesitancy, and suprapubic pain on the morning fo.

Oral antibiotic treats most children with UTI
https://www.mdedge.com/pediatrics/article/235439/infectious-diseases/oral-antibiotic-treats-most-children-uti
Jill Pivovarov

Feb 3rd, 2021 - Oral antibiotic treatment for 7-10 days works for most feverish children with uncomplicated urinary tract infection (UTI), reported Tej K. Mattoo, MD, of Wayne State University, Detroit, and associates.

Potentially Practice-Changing Bacterial Therapy Trials Analyzed
https://www.staging.medscape.com/viewarticle/940076

Oct 30th, 2020 - A new formulation of an existing antibacterial agent and a potential therapeutic approach to a challenging clinical problem were the focus of a session on potentially practice-changing clinical trials in antimicrobial therapy presented during IDWe...

see more →